EICHORCondition: Polycystic Ovary Syndrome · Sponsor: Khyber Medical University Peshawar
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This randomized controlled clinical trial aims to evaluate the effect of orlistat on the metabolic and hormonal features of women with polycystic ovary syndrome (PCOS). Eligible women diagnosed with PCOS according to the Rotterdam criteria will be randomly assigned to receive either orlistat plus standard lifestyle advice or placebo plus standard lifestyle advice for three months. The study will assess the effect of orlistat on hormonal parameters, glucose metabolism, lipid profile, liver function, anthropometric measures, non-alcoholic fatty liver disease, and quality of life to determine its effectiveness as an adjunctive treatment for women with PCOS.
This description comes directly from the study's public registry record.
Prof Dr Ruqqiya Sultana, MBBS · +92 314 5014992 · ruqqia_sultana@yahoo.com
Dr Noman Arif, PhD · +92 345 3059391 · nomanarif@kmu.edu.pk
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Females aged 18-45 years. * Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam Criteria (presence of any two of the following): * Oligomenorrhea or amenorrhea. * Clinical or biochemical hyperandrogenism. * Polycystic ovaries on ultrasonography. * Body mass index (BMI) between 18.5 and 35 kg/m² (Asian criteria). Exclusion Criteria: * Current or recent use of oral contraceptives, ovulation induction medications, anti-obesity medications, cholesterol-lowering medications, or other therapies/supplements known to affect insulin physiology or androgen metabolism (e.g., inositols, curcumin, lipoic acid, cinnamon, gymnemic, or other botanical extracts). * Women undergoing in vitro fertilization (IVF) treatment. * Known congenital adrenal hyperplasia, thyroid disorders, hyperprolactinemia, or diabetes mellitus. * Presence of severe renal or liver disease. * Menopausal, pregnant, or breastfeeding women. * Anti-Müllerian Hormone (AMH) \< 0.7 ng/mL.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Ayub Teaching Hospital | Abbottābād, Khyber Pakhtunkhwa, Pakistan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07747909